KHKatja Marja Hakkarainen

Katja Marja Hakkarainen

*This is an algorithmically generated author record based on publicly available information.

Katja Marja Hakkarainen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Auli Verkkoniemi-Ahola

    Clinical Neurosciences, Neurology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00029, Helsinki, Finland

    2 shared publications
  • Jan Hillert

    Karolinska Institute, Tomtebodavägen 18A, 171 77 Stockholm, Sweden

    2 shared publications
  • Kiliana Suzart-Woischnik

    Bayer AG, Building S102, 148, 13353 Berlin, Germany

    2 shared publications
  • Meritxell Sabidó

    Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany

    2 shared publications
  • Pasi Korhonen

    StatFinn-EPID Research, Metsänneidonkuja 6, 02130 Espoo, Finland

    2 shared publications
  • Sarah Burkill

    Karolinska Institute, Solnavägen 1, 171 77 Solna, Sweden

    2 shared publications

Latest Publications

  • Open Access

    Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden

    by Marta Korjagina, Katja M Hakkarainen, Sarah Burkill, Yvonne Geissbühler, Meritxell Sabidó, Nicholas Everage, Kiliana Suzart-Woischnik, Riho Klement, Jan Hillert, Auli Verkkoniemi-Ahola, et al.


  • Open Access

    Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden

    by Katja Marja Hakkarainen, Rosa Juuti, Sarah Burkill, Yvonne Geissbühler, Meritxell Sabidó, Catrinel Popescu, Kiliana Suzart-Woischnik, Jan Hillert, Miia Artama, Auli Verkkoniemi-Ahola, et al.

    Background: Our aim was to estimate and compare the prevalence of adverse pregnancy outcomes among pregnant women with multiple sclerosis (MS) exposed to interferon beta (IFNB) and among women with MS unexposed to any MS disease-modifying drug (MSDMD). Methods: This cohort study used Finnish (1996–2014) and Swedish (2005–2014) national register data. Women with MS having IFNB dispensed 6 months before or during pregnancy as the only medication were considered as IFNB exposed (only IFNB-exposed), whereas women with MS unexposed to any MSDMD were considered unexposed (MSDMD-unexposed). Prevalence was described and compared using log-binomial or logistic regression and adjusted for potential confounders including maternal age and comorbidity. Results: Among 2831 pregnancies, 2.2% of the only IFNB-exposed and 4.0% of the MSDMD-unexposed women had serious adverse pregnancy outcomes [elective termination of pregnancy due to foetal anomaly (TOPFA), major congenital anomaly (MCA) in live, or stillbirth]. After adjustments, the prevalence of serious adverse pregnancy outcomes was lower among the only IFNB-exposed compared with the MSDMD-unexposed [relative risk 0.55, 95% confidence interval (CI) 0.31–0.96]. The prevalence of individual outcomes, including MCA, spontaneous abortions, and stillbirths was not increased with IFNB exposure. Women with MS exposed to IFNB appeared more likely to terminate their pregnancy for reasons other than foetal anomaly, compared with MSDMD-unexposed pregnant MS patients (odds ratio 1.71, 95% CI 1.06–2.78). Conclusion: In this large cohort study, no increase in the prevalence of adverse pregnancy outcomes was observed in women with MS exposed to IFNB compared with MS patients unexposed to any MSDMDs. This study together with other evidence led to a change in the labels of the IFNB products in September 2019 in the European Union, and IFNB use today may be considered during pregnancy, if clinically needed.